I have to laugh at all you retail shorts and naysayers. I and other tried to tell you is was a small hiccup and the hold would be lifted very soon. There simply isn't better options for these patients and the fact is this treatment along with other CarT therapy is highly effective.
Ok please tell me your not a hematologist because you clearly don't understand the purpose of flu-cy in this setting. It's the same reason as conditioning for ASCT. You have to condition the immune system.
Starting to add a position here. Will do so gradually over the next 3-4 days. IMO enter on this weakness and forget you own these shares. Take a peak in Dec after ASH conference and you will be pleasantly surprised.
Exactly. It's a non event. Biggest buying opportunity you'll likely get.
yes conditioning is required to maximize the proliferation of the autologous Tcells but you can use a milder conditioning such as cyclophosphamide alone. You don't always need the most aggressive and often difficult to handle flu-cy.
wow that's a seriously uninformed post you just made. You do realize fludarabine is a common drug for CLL and also frequently used for conditioning ASCT. combined with Cyclophosphamide is often the conditioning regiment to prime the immune system for transplants. You need to get rid of the suppressor Tregs and make room for transplants to take. Same as the case for CART although you can use cy along rather Flu-Cy as they will no doubt do from now on with this construct.
Flu-cy is common conditioning regiment for ASCT and is logical for CART. It seems however it may prove to good of a conditioning regiment for this construct. iMO this will prove to be a non event. Flu-cy will be the standard conditioning regiment once the management of CSR is better understood.
THis is a non event. Its all related to their attempt to add fludarabine as others have tried to their conditioning regiment. Flu-Cy although great conditioning for ASCT its proving dangerous for CARTs.
What do you think of Cellectis CLLS. The are on of the only companies working on allogeneic CART compared to JUNO and KITEs autologous CART. Granted Cellectis is far behind both clinically but nonetheless they have show two early CRs in Peds. If they can prove their allogeneic is as good as auto then this will be disruptive for both JUNO and KiTE
In minimal disease they won't work especially in tumors that are relatively antigenically silent I,e PANC. Trial after trial have failed. Perhaps if we can figure out how to efficiently expand T cell clones in Vivo then maybe but until then I stand by my comment that cancer vaccines will fail and will especially fail in a minimal disease setting,
Ok I'll bite. I always enjoy arguing with self proclaimed "experts" on message boards. Do tell me Mr Gene what comment that I posted was so ridiculous? It is a fact you can not have cytotoxic T cell expansion without the presence of antigens. Remember its an T Cell expansion is via an autocrine response that is at its core dependent on antigens.
Check point inhibitors work because they don't rely on T cell clonal expansion. Fundamentally the immune system wants to fight the cancer but the cancer has learned to evade this by over expressing the T cell co receptor PDL1 which puts the brakes on. Check point inhibitors releases this brake.
its a double edge though, vaccines can't work if you never get T cell expansion and you are unlikely to get T Cell expansion if the antigen is rare i.e. minimal disease. This is why imo cancer vaccines will not work.